Adamantane derivative

Bromantane is a lipophilic adamantane stimulant-anxiolytic developed in the Soviet Union and marketed in Russia as Ladasten for asthenic disorders. A 30-person, single-blind placebo trial reported faster and greater symptom relief, while a 728-patient uncontrolled programme reported improvement from day 3; neither result has been independently replicated. Its best-supported mechanism is not direct receptor agonism or dopamine transporter blockade, but altered expression of dopamine-synthesis enzymes in animals.